10.125  0.115 (1.15%)		04-20 11:08
Open: 10.25 High: 10.25 Volume: 4,598		Pre. Close: 10.01 Low: 10.125 Market Cap: 51(M)

Short term
Mid term
Targets	6-month :	13.78	1-year :	16.09
Resists	First :	11.8	Second :	13.78
Pivot price	9.52
Supports	First :	9.79	Second :	8.56
MAs	MA(5) :	9.73	MA(20) :	9.7
	MA(100) :	12.07	MA(250) :	11.12
MACD	MACD :	-0.4	Signal :	-0.6
%K %D	K(14,3) :	72	D(3) :	55.2
RSI	RSI(14): 52.6
52-week	High :	14.76	Low :	7.09

Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.
[ DXR ] has closed Bollinger Bands are 16.8% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

If tomorrow:	Open lower	Open higher
High:	10.27 - 10.31	10.31 - 10.35
Low:	9.41 - 9.45	9.45 - 9.5
Close:	9.94 - 10.01	10.01 - 10.09

Daxor Corporation, a medical device company, provides blood volume measurement technology focused on blood volume testing. The company develops and markets BVA-100 Blood Volume Analyzer, a diagnostic blood test to provide safe, accurate, objective quantification of blood volume status and composition compared to patient-specific norms for used in a broad range of medical and surgical conditions. The company was formerly known as Idant Corporation and changed its name to Daxor Corporation in May 1973. Daxor Corporation was incorporated in 1971 and is headquartered in Oak Ridge, Tennessee.

Tue, 14 Apr 2026
(DXR) and the Role of Price-Sensitive Allocations - Stock Traders Daily

Fri, 10 Apr 2026
DAXOR (DXR) CEO Michael Feldschuh adds 1,000 shares in open-market buy - Stock Titan

Wed, 08 Apr 2026
24-hour blood volume testing reaches Ohio heart failure center - Stock Titan

Tue, 31 Mar 2026
Insider Buying: Robert Michel Acquires Shares of Daxor Corp (DXR) - GuruFocus

Tue, 31 Mar 2026
Michel, Daxor CFO, buys $9,900 in DXR stock - Investing.com

Thu, 26 Mar 2026
Daxor’s Blood Volume Analysis Metric Validated as Uniquely - GlobeNewswire

Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.	Outperform
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).	Neutral
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.	Underperform
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.	Outperform
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.	Outperform
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.	Underperform

Exchange: NASDAQ
Sector: Healthcare
Industry: Medical - Instruments & Supplies
Shares Out	0 (M)
Shares Float	0 (M)
Held by Insiders	5.83e+006 (%)
Held by Institutions	2.57e+006 (%)
Shares Short	0 (K)
Shares Short P.Month	0 (K)

EPS	26690
EPS Est Next Qtrly	0
EPS Est This Year	0
EPS Est Next Year	0
Book Value (p.s.)	1.63
Profit Margin	34 %
Operating Margin	359.1 %
Return on Assets (ttm)	-9 %
Return on Equity (ttm)	660.5 %
Qtrly Rev. Growth	22.4 %
Gross Profit (p.s.)	0.26
Sales Per Share	-0.01
EBITDA (p.s.)	-0.01
Qtrly Earnings Growth	0 %
Operating Cash Flow	0 (M)
Levered Free Cash Flow	0 (M)

PE Ratio	0
PEG Ratio	0
Price to Book value	6.25
Price to Sales	-626563
Price to Cash Flow	3120.44

Dividend	3280
Forward Dividend	3600
Dividend Yield	32000%
Dividend Pay Date	Invalid DateTime.
Ex-Dividend Date	Invalid DateTime.